Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate (ANES)
Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.
Sexual functions remain very important in men with prostate cancer. However sexual functions are deteriorating fast with course of the disease. The influence of CPA on sexual functions remains controversial. IIEF-5 erectile dysfunction questionnaire is currently widely used validated simple scoring system for diagnosing of erectile dysfunction and belongs to most used systems in Czech Republic. At present there are no data on CPA influence on IIEF-5 scored erectile dysfunction within the use of its indication in prostate cancer.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prospective Observational Non-interventional Study of Correlation of Treatment With Androcur, Disease Stage, Testosterone Level, Age With Sexual Function and Erectile Dysfunction (Measured by IIEF-5 Validated Questionnaire)|
- Correlation of treatment with Androcur (concomitant treatment), disease stage, testosterone level, age with erectile dysfunction (measured by IIEF-5 validated questionnaire) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Correlation of PSA level and erectile dysfunction [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Sexual activity of Czech patients with inoperable prostate cancer [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
|Study Start Date:||August 2009|
|Study Completion Date:||August 2011|
Drug: Cyproterone Acetate (Androcur, BAY94-8367)
Patients in regular clinical practice receiving Androcur according to local drug information